Chemoradiotherapy for advanced gastric cancer

Tsunehiro Takahashi, Yoshiro Saikawa, Kazumasa Fukuda, Norihito Wada, Hirofumi Kawakubo, Hiroya Takeuchi, Junichi Fukada, Osamu Kawaguchi, Hiromasa Takaishi, Naoyuki Shigematsu, Yuukou Kitagawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In the US and Europe, chemoradiotherapy has become a standard treatment not only for head and neck cancer, esophageal cancer, pancreatic cancer, and rectal cancer, but also for gastric cancer. In particular, chemoradiotherapy has been established as an adjuvant therapy. In Japan, it has not been established as a standard treatment. Its indications are limited, and it is often performed as palliative care. Disadvantages of radiation therapy for gastric cancer include the difficulty of establishing the area to irradiate due to peristaltic movement, risk of perforation and ulceration from high-dose radiation, and ineffectiveness against adenocarcinoma with low radiosensitivity. In recent years, technological advancement of radiation therapy has enabled pinpoint accuracy in the treatment of primary gastric lesions and regional lymph nodes. There has been much anticipation that chemoradiotherapy will become a part of multidisciplinary treatment for advanced cancer. This report describes the current state of chemoradiotherapy for gastric cancer in Japan and overseas, and outlines our approach to locally advanced gastric cancer.

Original languageEnglish
Pages (from-to)2464-2468
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume39
Issue number13
Publication statusPublished - 2012 Dec

Fingerprint

Chemoradiotherapy
Stomach Neoplasms
Japan
Radiotherapy
Therapeutics
Radiation Tolerance
Esophageal Neoplasms
Rectal Neoplasms
Head and Neck Neoplasms
Pancreatic Neoplasms
Palliative Care
Stomach
Adenocarcinoma
Lymph Nodes
Radiation
Neoplasms

Keywords

  • Chemoradiotherapy
  • Local advanced gastric cancer
  • Preoperative chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemoradiotherapy for advanced gastric cancer. / Takahashi, Tsunehiro; Saikawa, Yoshiro; Fukuda, Kazumasa; Wada, Norihito; Kawakubo, Hirofumi; Takeuchi, Hiroya; Fukada, Junichi; Kawaguchi, Osamu; Takaishi, Hiromasa; Shigematsu, Naoyuki; Kitagawa, Yuukou.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 39, No. 13, 12.2012, p. 2464-2468.

Research output: Contribution to journalArticle

Takahashi T, Saikawa Y, Fukuda K, Wada N, Kawakubo H, Takeuchi H et al. Chemoradiotherapy for advanced gastric cancer. Japanese Journal of Cancer and Chemotherapy. 2012 Dec;39(13):2464-2468.
Takahashi, Tsunehiro ; Saikawa, Yoshiro ; Fukuda, Kazumasa ; Wada, Norihito ; Kawakubo, Hirofumi ; Takeuchi, Hiroya ; Fukada, Junichi ; Kawaguchi, Osamu ; Takaishi, Hiromasa ; Shigematsu, Naoyuki ; Kitagawa, Yuukou. / Chemoradiotherapy for advanced gastric cancer. In: Japanese Journal of Cancer and Chemotherapy. 2012 ; Vol. 39, No. 13. pp. 2464-2468.
@article{f9e0f62dba0e4f00af40c75415f352d8,
title = "Chemoradiotherapy for advanced gastric cancer",
abstract = "In the US and Europe, chemoradiotherapy has become a standard treatment not only for head and neck cancer, esophageal cancer, pancreatic cancer, and rectal cancer, but also for gastric cancer. In particular, chemoradiotherapy has been established as an adjuvant therapy. In Japan, it has not been established as a standard treatment. Its indications are limited, and it is often performed as palliative care. Disadvantages of radiation therapy for gastric cancer include the difficulty of establishing the area to irradiate due to peristaltic movement, risk of perforation and ulceration from high-dose radiation, and ineffectiveness against adenocarcinoma with low radiosensitivity. In recent years, technological advancement of radiation therapy has enabled pinpoint accuracy in the treatment of primary gastric lesions and regional lymph nodes. There has been much anticipation that chemoradiotherapy will become a part of multidisciplinary treatment for advanced cancer. This report describes the current state of chemoradiotherapy for gastric cancer in Japan and overseas, and outlines our approach to locally advanced gastric cancer.",
keywords = "Chemoradiotherapy, Local advanced gastric cancer, Preoperative chemotherapy",
author = "Tsunehiro Takahashi and Yoshiro Saikawa and Kazumasa Fukuda and Norihito Wada and Hirofumi Kawakubo and Hiroya Takeuchi and Junichi Fukada and Osamu Kawaguchi and Hiromasa Takaishi and Naoyuki Shigematsu and Yuukou Kitagawa",
year = "2012",
month = "12",
language = "English",
volume = "39",
pages = "2464--2468",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "13",

}

TY - JOUR

T1 - Chemoradiotherapy for advanced gastric cancer

AU - Takahashi, Tsunehiro

AU - Saikawa, Yoshiro

AU - Fukuda, Kazumasa

AU - Wada, Norihito

AU - Kawakubo, Hirofumi

AU - Takeuchi, Hiroya

AU - Fukada, Junichi

AU - Kawaguchi, Osamu

AU - Takaishi, Hiromasa

AU - Shigematsu, Naoyuki

AU - Kitagawa, Yuukou

PY - 2012/12

Y1 - 2012/12

N2 - In the US and Europe, chemoradiotherapy has become a standard treatment not only for head and neck cancer, esophageal cancer, pancreatic cancer, and rectal cancer, but also for gastric cancer. In particular, chemoradiotherapy has been established as an adjuvant therapy. In Japan, it has not been established as a standard treatment. Its indications are limited, and it is often performed as palliative care. Disadvantages of radiation therapy for gastric cancer include the difficulty of establishing the area to irradiate due to peristaltic movement, risk of perforation and ulceration from high-dose radiation, and ineffectiveness against adenocarcinoma with low radiosensitivity. In recent years, technological advancement of radiation therapy has enabled pinpoint accuracy in the treatment of primary gastric lesions and regional lymph nodes. There has been much anticipation that chemoradiotherapy will become a part of multidisciplinary treatment for advanced cancer. This report describes the current state of chemoradiotherapy for gastric cancer in Japan and overseas, and outlines our approach to locally advanced gastric cancer.

AB - In the US and Europe, chemoradiotherapy has become a standard treatment not only for head and neck cancer, esophageal cancer, pancreatic cancer, and rectal cancer, but also for gastric cancer. In particular, chemoradiotherapy has been established as an adjuvant therapy. In Japan, it has not been established as a standard treatment. Its indications are limited, and it is often performed as palliative care. Disadvantages of radiation therapy for gastric cancer include the difficulty of establishing the area to irradiate due to peristaltic movement, risk of perforation and ulceration from high-dose radiation, and ineffectiveness against adenocarcinoma with low radiosensitivity. In recent years, technological advancement of radiation therapy has enabled pinpoint accuracy in the treatment of primary gastric lesions and regional lymph nodes. There has been much anticipation that chemoradiotherapy will become a part of multidisciplinary treatment for advanced cancer. This report describes the current state of chemoradiotherapy for gastric cancer in Japan and overseas, and outlines our approach to locally advanced gastric cancer.

KW - Chemoradiotherapy

KW - Local advanced gastric cancer

KW - Preoperative chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84875046503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875046503&partnerID=8YFLogxK

M3 - Article

C2 - 23235166

AN - SCOPUS:84875046503

VL - 39

SP - 2464

EP - 2468

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 13

ER -